John Huemoeller, CEO of AXIM Biotechnologies Inc AXIM, recently participated in Benzinga's Virtual HealthCare Summit 2024.
AXIM Biotechnologies is an international healthcare solutions company targeting ocular biomarkers. AXIM Eye is working with two highly specialized point-of-care lab testing solutions designed specifically to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis.
The company's diagnostic tools can also help detect early signs of Parkinson's disease. AXIM believes many other brain-based diseases can be detected through tears.
Learn more here:
Featured photo by Marina Vitale on Unsplash.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.